Emerging Screening Criteria (Andermann synthesis of Wilson-Jungner)
This checklist updates the classic Wilson-Jungner criteria for disease screening to reflect advances in genomics and modern public health challenges. It helps assess whether a screening program is appropriate and beneficial in today's healthcare context.
At a glance
Use when
Evaluating the justification and design of new or existing screening programs, especially in the context of genomics or personalized medicine.
Avoid when
Rapid, high-throughput decision-making requiring numerical scoring; when detailed economic modeling is the primary need.
Inputs
Information on the disease, screening test performance, population impact, ethical considerations, and healthcare system capacity.
Outputs
Structured assessment of the appropriateness and feasibility of a screening program.
How it works
Developed by Andermann et al. in 2008, this updated set of screening criteria builds upon the original Wilson-Jungner principles established by WHO in 1968. The revised framework incorporates ethical, social, and organizational considerations relevant to genomic and personalized medicine, offering a more comprehensive evaluation of screening programs in contemporary settings.
- HTA domains
- Clinical Effectiveness, Organisational aspects, Patient and Social Aspects
- Assumptions
- Screening programs should be evidence-based, equitable, and integrated within healthcare systems with attention to emerging challenges like genomics and overdiagnosis.
- Strengths
- Incorporates modern ethical, social, and organizational factors; applicable to genetic and non-genetic screening; builds on a well-established foundation.
- Limitations
- May require adaptation for specific technologies or populations; does not provide quantitative thresholds for decision-making.
- Also known as
- Andermann screening criteria, Revised Wilson-Jungner criteria, Genomic-age screening criteria
Questions this answers
- › Is there a clear and treatable condition suitable for screening?
- › Is the screening test valid, reliable, and acceptable to the population?
- › Are the benefits of screening greater than the harms, including overdiagnosis and anxiety?
- › Are psychosocial, ethical, and equity issues addressed in the screening program?
- › Is there evidence of effectiveness from research studies?
- › Are there adequate resources and follow-up systems in place for diagnosis and treatment?
References & sources
Similar by meaning
- ACCE Model Process for Evaluating Genetic Tests
- MSAC evaluation framework for genetic and genomic tests (value-of-knowing / personal utility)
- EuroGentest Clinical Utility Gene Card (CUGC)
- Threshold Approach to Clinical Decision Making (Pauker-Kassirer)
- National framework for reviewing codependent technologies (personalised medicines)
Beta record. Generated from the primary source via AI extraction and independent audit, pending final human review.